Drug Information

Drug General Information
Drug ID
D01LNG
Former ID
DCL000714
Drug Name
Balicatib
Synonyms
N-[1-(cyanomethylcarbamoyl)cyclohexyl]-4-(4-propylpiperazin-1-yl)benzamide
Drug Type
Small molecular drug
Indication Osteoporosis [ICD9: 733.0, V07.4; ICD10:M80-M81, Z79.890] Discontinued in Phase 2 [536957], [542791]
Company
Novartis
Formula
C23H33N5O2
InChI
InChI=1S/C23H33N5O2/c1-2-14-27-15-17-28(18-16-27)20-8-6-19(7-9-20)21(29)26-23(10-4-3-5-11-23)22(30)25-13-12-24/h6-9H,2-5,10-11,13-18H2,1H3,(H,25,30)(H,26,29)
InChIKey
LLCRBOWRJOUJAE-UHFFFAOYSA-N
CAS Number
CAS 354813-19-7
PubChem Compound ID
10201696
PubChem Substance ID
15199835, 22593687, 40316219, 46519853, 57374376, 77188764, 103473236, 123055334, 134339213, 135251926, 172918185, 198959058, 210275181, 210280821, 223366191, 223366692, 223385368, 223739501, 227782416, 242059799, 248617778, 251910363, 251971359, 252160774, 252436744, 252451020, 252671597
Target and Pathway
Target(s) Cathepsin K Target Info Inhibitor [536957]
KEGG Pathway Lysosome
Osteoclast differentiation
Toll-like receptor signaling pathway
Rheumatoid arthritis
NetPath Pathway TGF_beta_Receptor Signaling Pathway
RANKL Signaling Pathway
IL2 Signaling Pathway
Reactome Collagen degradation
Degradation of the extracellular matrix
Activation of Matrix Metalloproteinases
Trafficking and processing of endosomal TLR
MHC class II antigen presentation
WikiPathways RANKL/RANK Signaling Pathway
Osteoclast Signaling
References
Ref 536957Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008 Dec;13(4):609-27.
Ref 542791(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7861).
Ref 536957Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008 Dec;13(4):609-27.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.